ESR1 and breast cancer: Although 1% is the recommended cut-off to define ER positivity (5), recent evidences revealed that tumors with low ER levels (1-9%) display a clinical behavior more similar to ER-negative BC, both in terms of response to neoadjuvant chemotherapy and prognosis thus suggesting that threshold of 10% should be used in clinical practice for therapeutic decisions (17).